Evidence-Based Complementary and Alternative Medicine

Research Article

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Table 3

Proportion of peripheral blood immune cells in the two groups before and after treatment (median (P25, P75)).


	Control group (%)		value	Observation group (%)		value
	Before treatment	After treatment	value	Before treatment	After treatment	value

CD3⁺	75.76 (47.78, 87.79)	75.18 (52.36, 82.31)	0.915	74.54 (51.23, 80.31)	73.61 (50.31, 81.24)	0.769
CD3⁺ CD4⁺	48.89 (18.97, 65.12)	39.6 (19.02, 78.68)	0.034	45.36 (17.65, 71.62)	49.75 (13.64, 74.16)	0.054
CD3⁺CD8⁺	33.89 (17.84, 45.26)	35.62 (20.69, 49.74)	0.549	36.16 (21.36, 48.37)	34.15 (19.65, 47.59)	0.512
CD4⁺/CD8⁺	1.65 (0.61, 2.89)	1.09 (0.48, 2.84)	0.048	1.69 (0.69, 2.79)	2.43 (0.64, 3.86)	0.019
CD3⁻CD56⁺	9.65 (5.24, 41.26)	8.25 (5.81, 37.64)	0.031	9.26 (6.31, 42.36)	14.26 (5.96, 36.16)	0.023
CD3⁺CD56⁺	3.68 (0.42, 10.29)	3.45 (0.59, 9.78)	0.794	3.78 (0.39, 11.29)	4.22 (0.57, 9.78)	0.145
CD 14⁺	4.78 (0.23, 32.04)	5.21 (0.02, 24.17)	0.359	5.61 (0.29, 36.19)	6.26 (0.16, 30.26)	0.278
CD 19⁺	8.41 (2.71, 17.41)	8.14 (5.78, 37.26)	0.571	7.89 (2.61, 26.45)	11.45 (5.14, 33.15)	0.036
CD4⁺ CD25high⁺ FOXP3⁺	4.74 (0.04, 11.68)	3.36 (0.15, 12.27)	0.401	4.16 (0.12, 12.31)	5.48 (0.34, 16.45)	0.141

Versus control group, , .